Supernus Pharmaceuticals' net profit under GAAP for 9 months of 2020 was $96.182 million, up 20.3% from $79.927 million the previous year. Revenue increased 28.9% to $376.84 million, compared to $292.309 million a year earlier.
Supernus Pharmaceuticals' net profit under GAAP for 9 months of 2020 was $96.182 million, up 20.3% from $79.927 million the previous year. Revenue increased 28.9% to $376.84 million, compared to $292.309 million a year earlier. 
ir.supernus.com
English (US) 